The galanin N-terminal fragment [galanin-(1-16) The 29-amino-acid-long C-terminal amidated peptide galanin (GAL) (1) has been shown to be widely distributed in the central nervous system of mammals (2-6). GAL-like immunoreactivity has been localized, among other brain regions, in the septal area (4-8) where GAL coexists with acetylcholine in rat (7) and monkey (9) in a subpopulation of cholinergic cell bodies projecting to the hippocampus. and equilibrium binding studies with 1251I-labeled GAL (125I-GAL) have shown a high density of putative high-affinity GAL receptors in the ventral part of the hippocampus (13).
role in the receptor-ligand interactions.
The 29-amino-acid-long C-terminal amidated peptide galanin (GAL) (1) has been shown to be widely distributed in the central nervous system of mammals (2) (3) (4) (5) (6) . GAL-like immunoreactivity has been localized, among other brain regions, in the septal area (4) (5) (6) (7) (8) where GAL coexists with acetylcholine in rat (7) and monkey (9) in a subpopulation of cholinergic cell bodies projecting to the hippocampus. Autoradiographic (10) (11) (12) and equilibrium binding studies with 1251I-labeled GAL (125I-GAL) have shown a high density of putative high-affinity GAL receptors in the ventral part of the hippocampus (13) .
In the ventral, but not in the dorsal, hippocampus GAL has been shown to inhibit, in a dose-dependent manner, the release of acetylcholine both in vitro and in vivo (12) . A possible role for GAL as presynaptic modulator of the cholinergic function in the ventral hippocampus has been suggested by a recent electrophysiological study (14) and a behavioral study (15) . Interactions between acetylcholine and GAL in the ventral hippocampus are not restricted to presynaptic sites but also involve actions that are considered postsynaptic (16) such as the GAL-mediated inhibition of the muscarinic agonist-stimulated breakdown of inositol phospholipids in the ventral hippocampus (17) and GAL inhibition of acetylcholine on a t-maze memory task in ventral forebrain lesioned rats (33) .
Previous studies carried out on intestinal smooth muscle showed the importance of the N-terminal portion of GAL for biological activity (18, 19) . Furthermore, N-terminal GAL fragments and analogs were able to mimic the effects of GAL on the pancreatic 83-cell line Rin m 5F, inhibiting forskolinstimulated cAMP production and insulin release (20) .
In this study, we focus our attention on the structureactivity relationship for the N terminus of GAL at receptors in the ventral hippocampus of the rat. Using equilibrium binding and autoradiographic techniques, we compare the synthetic N-terminal fragment GAL-(1-16) with rat GAL-(1-29) for its ability to displace 1251I-GAL from its receptors.
GAL-(1-16) is also tested for its ability to inhibit the scopolamine-induced acetylcholine release in vivo and carbacholstimulated inositol phospholipid breakdown in a slice preparation from the rat ventral hippocampus. The importance of [Trp2] in the activity of the N-terminal fragment is examined.
MATERIALS AND METHODS Materials. Na125I (2500 Ci/mmol; 1 Ci = 37 GBq) and myo-[3H]inositol (35 Ci/mmol) were purchased from Amersham. All other reagents were from Sigma. Amino acid derivatives and resins were from Bachem.
Animals. CD-COBS adult male rats (180-250 g) were used in the in vivo experiments. For all other studies, SpragueDawley adult male rats (200 g) were used. Porcine 1251-GAL (specific activity, 250-300 Ci/mmol), iodinated by the chloramine-T method, was prepared as described (13) and used in both the equilibrium binding experiments and the receptor autoradiographic analysis.
Preparation of GAL Fragments. Peptides were synthesized manually on p-methylbenzhydrylamine resin (0.35 mmol/g). Protected t-butoxycarbonyl-amino acids were serine (benzyl-), threonine (benzyl-), tyrosine (p-bromobenzyloxycarbonyl-), histidine (dinitrophenyl-), and D-and L-tryptophan (formyl-). Asparagine and glutamine were coupled as active hydroxybenzotriazole esters. All other amino acids were activated by N,N'-dicyclohexylcarbodiimide in a molar ratio of 1:1. The protocol for stepwise solid-phase peptide synthesis using the t-butoxycarbonyl-benzyl protective group strategy has been published elsewhere (21) .
Removal of protection was carried out by low trifluoromethanesulfonic acid (22) , and the resin was washed with trifluoroacetic acid (2 x 1 min), dichloromethane (3 x 1 min), dimethylformamide (3 x 1 min), ethanol (2 x 1 min), and diethyl ether (1 x 1 min). The resin was dried under vacuum followed by final removal of protection by hydrogen fluoride containing 8% p-cresol and 2% ethanedithiol at 0°C for 40
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min. Purification of the cleaved peptides was carried out by HPLC on a C18 reversed-phase column.
Synthetic porcine GAL-(1-29) (Bachem) was digested with endoproteinase Asp-N (Boehringer Mannheim) at an enzyme/substrate ratio of 1:250 to generate three peptide fragments, GAL-(1-16), -(17-23), and - (24) (25) (26) (27) (28) (29) and 70-100 ;kg of a ventral hippocampal membrane preparation (P2) obtained as described (13) . Samples were incubated for 30 min at 370C. Incubation was terminated by the addition of 10 ml of Hepes/Krebs-Ringer solution followed by rapid filtration over Whatman GF/C filters, precoated for 5-6 hr in 0.3% polyethylenimine solution, and a subsequent rinse with 10 ml of cold buffer. Specific binding was defined as that displaceable by GAL (1 ,AM). Autoradiographic Binding Studies. The autoradiographic analysis of 1I'-GAL binding sites was carried out according to the procedure of Young and Kuhar (24) as described (11) .
Briefly, porcine GAL was iodinated with Na'251I by the chloramine-T method. Rats were perfused with ice-cold Tyrode's solution, and the brain and spinal cord were sectioned on a cryostat, followed by incubation with 1251I-GAL (-1.5 nM) for 45 min at room temperature. Sections were rinsed, dried by a stream of cold air, exposed to formalin vapors, and covered by 3H-sensitive film (Hyperfilm, Amersham). Unlabeled GAL-(1-29) and GAL-(1-16) fragment both at 0.1 or 1.0 ,M were added to the incubation medium. In Vivo Experiments. In the in vivo release experiments, a thin dialysis fiber was implanted, essentially as described by Ungerstedt (25) and Benveniste et al. (26) , in the hippocampi of anesthetized rats. The dialysis probe was implanted vertically into the ventral hippocampus of one side. The day after implantation, the dialysis tube was perfused at a constant rate of 2 ,ud/min with Ringer's solution (147 mM NaCl/3.4 mM CaCl2/4 mM KCI, pH 6.1) containing 10 ,M physostigmine.
The perfusate was discarded during the first 40 min and then collected at 20-min intervals. Endogenous acetylcholine collected in the samples was assayed by a sensitive and specific radioenzymatic method, as described by Consolo et al. (27) .
RESULTS
The specific binding of 125I-GAL-(1-29) ( (Fig. 2) . At a concentration of 100 nM, the unlabeled peptide GAL-(1-29) (Fig. 2b) , but not GAL-(1-16) (Fig. 2d) , showed a complete block in areas with (28), porcine (1), and rat (29) GAL differs only in four amino acid residues. These changes all occur in the 15-29 C-terminal fragment, whereas the N-terminal fragment is conserved among these species.
We demonstrate here that the N-terminal portion of the GAL molecule [GAL- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) ] is sufficient for recognition by high-affinity receptor sites for 1251-GAL in the rat forebrain and in the hippocampus in particular, as well as in the spinal cord. This is evidenced by the ability of GAL-(1-16) to displace the 125I-GAL in both equilibrium binding and autoradiography experiments. The affinity of the GAL-(1-16) is high (Kd 3 nM). pancreatic ,B cells has also been shown recently (20) . It should also be noted that the GAL-(1-16) that is generated both enzymatically and by solid-phase synthesis carries a free C-terminal carboxyl group, while the holopeptide GAL has a C-terminal amide.
Studies on the effect of GAL-(1-16) on the muscarinic agonist-mediated breakdown of [3H]inositol phospholipids demonstrate that the fragment is not only a ligand but a full agonist, as it produces the maximal inhibition caused by GAL- at the supramaximal concentration (1 ,uM) (17) . It is also shown that [D-Trp2]GAL-(1-16) at 1 ,uM cannot mimic the effects of GAL- . This is probably not fully explained by its substantially lower affinity, since some degree of receptor occupancy at 1 ,uM is expected. Thus, this substitution may affect both affinity and efficacy.
In vivo studies on the inhibition of the scopolamineinduced release of acetylcholine show that GAL-(1-16) behaves as an agonist in the presynaptic inhibitory control of acetylcholine release (12) . The fragment GAL-(1-16) appears to be less efficient than GAL-(1-29) when applied in the same dose (10 ,g/15 ,ul) (12) . This may be a reflection of the somewhat lower affinity in combination with different diffusion and degradation rates for the fragment and for the holopeptide; alternatively, the fragment GAL-(1-16) may be more effective at post-than at presynaptic receptors in the hippocampus.
The above results together with those obtained on smooth muscle preparations with GAL-(1-10) (18) or GAL-(1-20) (19) and with GAL-(1-15) on the pancreatic p-cell line Rin m SF (20) suggest that, unlike many other neuropeptides, the biological activity of the GAL molecule may reside in the N-terminal portion of the molecule rather than in the Cterminal portion. Studies with the C-terminal fragments [GAL- (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) ] (20) and -(17-29) (G.F., unpublished data) showed no activity in the pancreas or the hippocampus, respectively.
It is important to study the effects offragments and analogs of neuropeptides at different receptor sites that differ in their second messenger coupling such as the hippocampal (12, 13) GAL receptor that affects inositol phospholipid breakdown (17) versus pancreatic (30) GAL receptor, which inhibits K+ channels (31) and inhibits adenylate cyclase activity (32) . The GAL fragments may provide tools to define possible receptor subtypes. Another aim of the structure-activity relationship studies is to define the important amino acid residues and to produce ideas concerning the possible structure of neuropep- before injection of GAL- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) and/or scopolamine. The data are the means ± SEM from three animals. Interaction between GAL fragment and scopolamine: *P < 0.05 and **P < 0.01, split-plot and Tukey's test.
tide receptor ligands with pharmacological activities. Shortening the peptide by 13 amino acid residues, while retaining full agonist properties, may be a step in this direction.
